Page 448 - Feline Cardiology

Index 473

HCM and, 158, 159 restrictive cardiomyopathy in, 178 Breathing, CPCR and, 30
treatment of symptomatic cats with, tricuspid valve malformation in, 87 Brethine (terbutaline), 444
161 Biventricular heart failure, dilated indications, dosage, available sizes, 462
indications, dosage, available sizes, 444 cardiomyopathy and, 184 Brevipace (sotalol), 444
pulmonary arterial hypertension and, Blindness indications, dosage, available sizes, 449
390 heartworm disease and, 355 British shorthair cats, HCM in, 106, 118
references for, 464, 467, 468 hyperaldosteronism and, 405 Bronchodilator, heartworm disease and
systemic hypertension and, 436 systemic hypertension and, 331, 332 use of, 360
Bengal cats, HCM in, 106, 118 “Blind” thoracocentesis, for hospitalized Brown lungs, 266
Benzodiazepines, anesthesia for patient cats with HCM and dyspnea, 290 Brugia malayi, 355
with cardiac disease and, 417 Blocks, types of, 237 B-type natriuretic peptides, 72, 330
Beraprost, pulmonary arterial Blood pressure BUN
hypertension and, 390 abnormalities with, incidental findings, dilated cardiomyopathy and, 186
Beta-adrenergic blockers, anesthetic 332 elevated, arterial thromboembolism
management and, 415 measurement and, 309
Beta-agonists, for cats with asthma, 375 anesthesia in patient with cardiac HCM diagnosis and, 123
Beta blockers disease and, 418 restrictive cardiomyopathy and, 180
congestive heart failure and, 289, 435 indication for, 334 Bundle branch blocks, 237, 241–243
dilated cardiomyopathy and, 434–435 instrumentation for, 335 Buprenex (buprenorphine), indications,
feline cardiovascular disease and, reliable, patient evaluation and, 326 dosage, available sizes, 444
156–157 sedation of fractious or anxious cat Buprenorphine
HCM in people and, 155 and, 335–336 analgesia for arterial thromboembolism
HCM–compensated (“asymptomatic”) technique for, 334–336 in cat and, 310
and, 433 normal values, feline, inside covers anesthesia for feline cardiac patient
for hyperthyroid cats, 404 systemic hypertension and and, 414t, 417
progressive concentric hypertrophy, normal regulation of, 329–330 echocardiography and use of, 54
worsened SAM and, 166 pathways involved in long-term indications, dosage, available sizes, 444
ventricular tachycardia and, 236 regulation of, 330 premedication of cats with HCM and,
pitfalls to avoid, 234 white coat effect and unexplained 415
Beta-1 selective blockers, feline asthma elevations in, 330 Burmese cats
and, 376 Blood stasis dilated cardiomyopathy in, 184
Betapace (sotalol), 444 red blood cell aggregation in cats with primary endocardial fibroelastosis in,
indications, dosage, available sizes, 460 cardiac disease and, 116 206, 207
β-MHC thrombogenesis and, 306 Butorphanol, 462
etiology of HCM in humans and, 107 BNPs. See NT-proBNP analgesia for arterial thromboembolism
familial HCM in cats and, 106 Body weight, echocardiographically and, 310
Bezold-Jarisch reflex, 219 derived systolic performance for anesthesia, feline cardiac patient,
Biochemical profiles, arterial indexes, 60t 414t
thromboembolism and, 309, Bosentan, pulmonary arterial echocardiography and, 55
311 hypertension and, 390 indications, dosage, available sizes, 444
Biomarkers, cardiac, 69–73 Box induction with inhalant anesthetic, pleural effusion and, 21
appeal of, 149–150 fractious cats and, 418 B vitamins
assays, 71–72 Bradyarrhythmias, 213 indications, dosage, available sizes, 444
cardiac troponins, 70–71 anesthetic risk and, 412 references for, 467
categories of, 69 dilated cardiomyopathies and, 184 Bypass tract, 244
defined, 69 syncope and, 16
endothelin 1, 70 Bradycardia, 216 C
natriuretic peptides, 72–73 due to second- or third-degree AV Cachexia, heart failure treatment and, 295
Biomarkers, circulating block, CHF and, 270 Calan (verapamil), 445, 463
CHF and, 282–284 hypotensive shock-associated, 219 Calcium-channel blockers, 156
cardiac troponin I, 283–284 profound, syncope and, 15 anesthetic management and, 415
natriuretic peptides, 282–283 treatment of, in anesthetized cat, 419 congestive heart failure and, 289, 436
HCM and Bradycardia-tachycardia syndrome, dilated cardiomyopathy and, 435
cardiac troponin I, 150 243–244 HCM and, 155, 157–158
endothelin 1, 150 Bradykinin, ATII and, 265 HCM–compensated (“asymptomatic”)
natriuretic peptides, 148–150 Brain natriuretic peptides (See also B-type and, 433
Biosite Triage Meter, 71, 72 natriuretic peptides) progressive concentric hypertrophy,
Birman cats biologic effects of, 149 worsened SAM and, 166
dilated cardiomyopathy in, 184 congestive heart failure and, 282, 283 ventricular tachycardia and, pitfalls to
HCM in, 118 synthesis of, 148–149 avoid, 234